Q-omics provides the consensus-scored GPR180 profile across patient tissues and cancer cell-line models. GPR180 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GPR180 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GPR180 protein abundance shows 22,647 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, HNSC, and LUAD as cancer lineages where GPR180 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR180 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR180 survival associations across molecular data types. GPR180 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR180 RNA expression–survival associations across cancer types. High GPR180 expression shows unfavorable associations in LIHC, LGG, KIRP, HNSC, UVM and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for GPR180 RNA expression.
This table summarizes GPR180 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPR180. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR180 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, BLCA, COAD and KIRP. The HNSC box plot shows higher GPR180 RNA expression in tumor versus normal tissue (log2 FC = +1.024, t-test p < 0.001).
This table shows molecular features associated with GPR180 in patient tissues and cancer cell lines. In patient samples, GPR180 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR180 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
